Jarrow Formulas Ubiquinol QH-Absorb 100 mg Review

Yes — the 'QH-Absorb' branding refers to Jarrow's softgel-formulation work on top of the Kaneka QH raw material, which is the same patent-grade Japanese fermentation-derived ubiquinol used in Healthy Origins (#4), NOW Foods (#3), and Life Extension. The molecule itself is identical to every other Kaneka-licensed ubiquinol bottle. What Jarrow's softgel adds: medium-chain triglyceride (MCT) carrier oil pre-formulated inside the softgel shell, which improves absorption when taken without a fatty meal. If you take your CoQ10 with breakfast eggs or dinner with olive oil, the QH-Absorb branding adds nothing — generic Kaneka QH ubiquinol delivers the same plasma Q10. If you frequently dose with water or a low-fat snack, the carrier-oil pre-formulation is the small advantage over Healthy Origins' simpler softgel.

At the prices we read on Oct 11, 2026 there is no premium to weigh: Jarrow cost $27.05 for 60 softgels on Amazon US and Healthy Origins $29.99. Both bottles ship the same licensed Kaneka QH ubiquinol at 100 mg per softgel. Jarrow adds the carrier-oil softgel (a small absorption benefit if you do not take it with a fat meal), deeper documentation and wider store availability. An earlier version of this review listed Healthy Origins at $21 and called it the value pick; that price lead is gone for now, so compare the two on the day you buy.

Depends on age, statin status, and protocol. General longevity / 40+ baseline: 1 softgel/day with breakfast or dinner — 100 mg ubiquinol is the standard maintenance dose, covered by Hosoe 2007 pharmacokinetic data. Statin user with myalgia: 2 softgels/day with dinner — 200 mg matches the Banach 2015 meta-analysis protocol that showed significant myalgia reduction. Migraine prophylaxis: 3 softgels/day split AM/PM — 300 mg matches the Sandor 2005 trial protocol. CHF (under cardiologist supervision): 3 softgels/day split — matches the Q-SYMBIO 3×100 mg/day protocol. The 60-softgel bottle is a 2-month supply at 1/day, 1 month at 2/day, 20 days at 3/day.

Most users feel nothing in week 1 — CoQ10 is not a stimulant. Serum CoQ10 levels measurably rise on bloodwork by week 2-4 (Hosoe 2007 PK curve). Statin users with prior myalgia notice reduced muscle soreness + cramping in weeks 2-4. Energy / fatigue improvements show up in deficient populations (older adults, CHF patients) by weeks 4-8. Migraine frequency reduction emerges by weeks 8-12 (Sandor 2005 timeline). If you're under 40, healthy, and not on a statin, you may not feel anything at all — that's the expected response curve, and a sign to redirect the budget toward creatine or omega-3 where the felt-effect curves are steeper.

Jarrow has reformulated the QH-Absorb softgel a couple of times over the past decade — the shell colour, ink stamp, and exact carrier-oil composition have varied across production runs. The active ingredient (Kaneka QH ubiquinol at 100 mg) and the third-party verification of that 100 mg has remained consistent across reformulations. If you receive a bottle with a softgel that looks different from your previous order, check the supplement-facts panel to confirm 100 mg ubiquinol per softgel — the cosmetic changes don't affect the bioactive content. Production-run variation is normal for the brand.

Only for severe soy-allergy buyers. The softgel shell uses soy lecithin as an emulsifier — typical for ubiquinol softgels because the lipid-soluble payload needs a fat-carrier shell. The soy content is trace (a few mg of lecithin), not the protein-allergen fraction, so most soy-sensitive users tolerate it fine. If you're severely soy-allergic and need to avoid all soy derivatives, NOW Foods Ubiquinol (#3) is the switch: its panel lists no soy ingredients. Thorne CoQ10 (#7) is not — its gelcap is bovine gelatin with soy monoglycerides, and it is not vegetarian either.

Life Extension Super Ubiquinol (#5) adds PrimaVie shilajit at 100 mg/softgel on top of the same 100 mg Kaneka QH that Jarrow ships. Shilajit is a Himalayan mineral-rich resin used in Ayurveda; PrimaVie is the patent-grade standardised form. We used to cite published bioavailability data for Kaneka QH + shilajit here, showing ~30-40% higher peak plasma Q10. That citation was fabricated: the study, its authors and its journal placement do not exist, and the id attached to it belonged to a paper on small-intestinal bacterial overgrowth. No published trial pairs shilajit with CoQ10 in any journal. So the higher price — Life Extension at $32.81 against Jarrow at $27.05 for 60 softgels on Oct 11, 2026 — buys Life Extension's QC pedigree, not a demonstrated absorption gain. Jarrow's pre-formulated MCT carrier oil already closes most of the fasted-absorption gap, and it is the same licensed Kaneka QH molecule.

1. [1] Hosoe 2007 (Kaneka pharmacokinetics) PMID 16919858 — Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Pharmacokinetic study of Kaneka ubiquinol in healthy adults. Established the dose-response curve, safety profile up to 300 mg/day for 4 weeks, and the bioavailability advantage of the reduced form. The reference safety + PK paper for the exact Kaneka QH ubiquinol Jarrow ships.
2. [2] Zhang 2018 (ubiquinol vs ubiquinone) PMID 30302465 — Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men. Head-to-head comparison of ubiquinol vs ubiquinone supplementation in older men. Ubiquinol produced significantly higher plasma CoQ10 levels at equivalent oral doses — confirming the 2-4× bioavailability advantage of the reduced form in adults over 40 that justifies Jarrow's Kaneka QH form choice.
3. [3] Banach 2015 (statin myopathy meta) PMID 25440725 — Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Meta-analysis of 12 RCTs (n=575) on CoQ10 supplementation in statin users with myopathy. Pooled effect showed significant reduction in statin-induced muscle pain, weakness, cramps, and tiredness versus placebo. The 200 mg/day protocol that justifies Jarrow's 2-softgel statin-support dose.
4. [4] Mortensen 2014 (Q-SYMBIO) PMID 25282031 — The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. 420 chronic heart failure patients randomised to 3×100 mg/day Kaneka CoQ10 vs placebo for 2 years. CoQ10 group showed 43% reduction in major adverse cardiovascular events and significant reduction in cardiovascular mortality. The pivotal outcome trial that justifies Jarrow's 3-softgel CHF-protocol dose.
5. [5] Sandor 2005 (migraine) PMID 15728298 — Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. 42 migraine patients randomised to 3×100 mg/day CoQ10 vs placebo for 3 months. CoQ10 group showed significant reduction in migraine attack frequency, headache days, and days with nausea. The foundational migraine RCT that anchors Jarrow's 3-softgel migraine-prophylaxis protocol.
6. [6] Hernández-Camacho 2018 (review) PMID 29459830 — Coenzyme Q10 supplementation in aging and disease. Comprehensive review of CoQ10 in aging, cardiovascular disease, neurodegeneration, and statin-induced complications. Establishes the age-related decline curve (~50% drop by age 60 in heart and skeletal muscle) and the rationale for ubiquinol supplementation in adults over 40 — the population Jarrow's QH-Absorb is designed for.